Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21912)	6/5/1998 5:09:00 PM
From: medsunman	Read Replies (3) \| Respond to of 32384

Henry, I wanted to thank you and Peter Singleton for responding to my concerns last week re LGND's Targretin for diabetes. Last October-November when I made my initial LGND investment, it seemed as though you were more confident about Targretin for this indication. No one on this thread seems to talk about diabetes anymore. If I remember correctly, don't you have another bottle of wine bet with Andrew H over LGND's August price ($30/share)? What events do you see between now and then that will make that bottle go fromBoulder to Pittsburgh, rather than vice versa? My guess is that the only possible near term news that could help this stock would be positive Phase II results with either Panretin or Targretin against larger cancer markets (i.e. something other than KS or CTCL). Let us know what you see happening this summer. Thanks, Medsunman